Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries.
Conclusion Prescription drug coverage is associated with decreased use of classic cytotoxic chemotherapy and better survival among Medicare beneficiaries with myeloma, which suggests improved access to all existing treatment options. As oral targeted agents increasingly replace parenteral chemotherapy in oncology, adjustments in coverage policy are needed to ensure access to optimal treatment.
PMID: 30113885 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Olszewski AJ, Dusetzina SB, Trivedi AN, Davidoff AJ Tags: J Clin Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lymphoma | Medicare | Myeloma | Oral Cancer | Revlimid | Velcade